This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: ETH Zurich. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Anja Zabel: Innovator in Bioconjugate Technology
Introduction
Anja Zabel is a prominent inventor based in Zürich, Switzerland. She has made significant contributions to the field of bioconjugates, particularly in the context of cancer therapy. Her innovative work focuses on the development of antibodies bound to functionalized magnetic nanoparticles, which have the potential to revolutionize cancer treatment.
Latest Patents
Anja Zabel holds a patent for "Bioconjugates of antibodies and functionalized magnetic nanoparticles." This invention relates to antibodies that are useful in therapy and diagnosis. It specifically discloses bioconjugates comprising one or more antibodies bound to functionalized, magnetic nanoparticles. These bioconjugates are particularly useful in cancer therapy, especially for the removal of circulating tumor cells. The invention also pertains to specific functionalized magnetic nanoparticles and the manufacturing processes for these bioconjugates.
Career Highlights
Throughout her career, Anja Zabel has worked with esteemed institutions such as Universität Zürich and ETH Zurich. Her research has focused on the intersection of nanotechnology and immunotherapy, leading to advancements in targeted cancer treatments.
Collaborations
Anja has collaborated with notable colleagues, including Antoine Florent Herzog and Wendelin Jan Stark. These partnerships have further enriched her research and contributed to the development of innovative therapeutic solutions.
Conclusion
Anja Zabel's work in bioconjugate technology exemplifies the potential of combining nanotechnology with medical applications. Her contributions are paving the way for new cancer therapies that could significantly improve patient outcomes.